Single-arm trials for domestic oncology drug approvals in China
Main Authors: | Hong Zhang, Sen Liu, Chenghao Ge, Xiaozhen Liu, Yang Liu, Chen Yin, Yi Li, Jing An, Zhongtian Yan, Xiaoyuan Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
China Anti-Cancer Association
2023-11-01
|
Series: | Cancer Biology & Medicine |
Online Access: | https://www.cancerbiomed.org/content/20/11/799 |
Similar Items
-
Analysis of patient-reported outcomes in the approval of novel oncology drugs in the United States, 2017–2022Research in context
by: Chenghao Ge, et al.
Published: (2023-05-01) -
International oncology drug approvals for multiregional or single-country clinical trials: A systematic review
by: Min Zhang, et al.
Published: (2022-12-01) -
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
by: Valentina Tateo, et al.
Published: (2023-04-01) -
Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 Years
by: Rosa Falcone, et al.
Published: (2022-02-01) -
Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006–2021: a cross-sectional study
by: Yi Chen, et al.
Published: (2023-06-01)